Statin Usage in Parkinson’s Disease in Relation to Vascular Comorbidities and Risk Factors (P5.383)

Objective: To define statin usage in patients with Parkinson’s disease (PD) according to the presence of either a diagnostic indication, or a vascular risk factor indication, for use of such therapy. Background: Vascular disease and vascular risk factors are common in patients with PD, and statin therapy is indicated to reduce the risk of further vascular disease. Statins are also of interest in PD due to their potential neuroprotective effects. Methods: All patients attending the west of Scotland regional movement disorder clinic and prescribed dopaminergic therapy for PD were assessed. Electronic medical records were reviewed to obtain data for: any diagnostic indication for statin use; antiparkinson therapy; vascular risk factors; and statin prescription. The ASSIGN (Assessing cardiac risk using Scottish Intercollegiate Guidelines Network) risk scoring system was used to calculate 10 year cardiovascular risk for patients without a diagnostic indication for statin use. Results: In 441 PD patients, 59.9[percnt] were male, with a mean age of 68.9 years (SD 10.3). 174 patients (39.5[percnt]) had at least one diagnostic indication for statin use, of whom 136 patients (78.2[percnt]) were prescribed a statin. In the 267 cases (60.5[percnt]) without a diagnostic indication, 54 (20.2[percnt]) were aged over 75 years, leaving 213 cases for whom ASSIGN scoring was appropriate. 62 of these 213 cases (29.1[percnt]) had an ASSIGN score in the recommended treatment range for statin therapy (10 year risk; 20[percnt] or more), of whom 15 (24.1[percnt]) were prescribed statins. Conclusions: Implementation of statin therapy for PD patients is suboptimal, particularly for those with a risk factor indication. The reasons for this, and the clinical impact, merit further study. Disclosure: Dr. Cheng has nothing to disclose. Dr. Swallow has nothing to disclose. Dr. Grosset has nothing to disclose. Dr. Grosset has received personal compensation for activities with AbbVie, Astellas, Civitas, and InVentiv Health as a consultant and for activities with AbbVie, GE Healthcare, Merz, Teva Neuroscience, and UCB Pharma as a speaker.